sua lowering therapies: the why, the when, the how!
DESCRIPTION
sUA Lowering Therapies: The why, the when, the how!. Presenter:. Speaker Disclosure Statement. Name of presenter/speaker sUA Lowering Therapies: The why, the when, the how ! Financial Disclosure : Grants/Research Support Speaker Bureau/Honoraria Consulting Fees Other . - PowerPoint PPT PresentationTRANSCRIPT
sUA Lowering Therapies:The why, the when, the how!
Presenter:
Speaker Disclosure Statement
Name of presenter/speaker sUA Lowering Therapies:
The why, the when, the how!Financial Disclosure: – Grants/Research Support – Speaker Bureau/Honoraria – Consulting Fees – Other
Mean Serum Urate, µmol/L
Per
cent
age
of P
atie
nts
With
G
out F
lare
Rec
urre
nce
0
20
40
60
80
100
Reduction in Acute Flaresin Years 2 and 3 of Treatment1
N = 267
.
.
0
10
20
30
40
50
0-4 4-8 8-12 12-16 16-20 20-24 24-28
Time interval (weeks)
Subj
ects
, %
Febuxostat 80 mg Allopurinol 300/200 mg